Haoran Wang

Jan 21, 2025 | dx.doi.org | Shuai Wang |Haoran Wang |Jiguo Tu |Lei Huang

Jan 14, 2025 | onlinelibrary.wiley.com | Haoran Wang |Lei Huang |Xiaomei Liu

References 1, , , , and , “ Model Analysis and Simulation of Traction System for Medium-Speed Maglev Traffic With Single-Sided Ironless Permanent Magnet Linear Synchronous Motor,” in Proceedings of the 2019 22nd International Conference on Electrical Machines and Systems (ICEMS) (Harbin, China: IEEE, 2019), 1–4.

Dec 5, 2024 | mdpi.com | Jianhua Zhang |Rong Liu |Haoran Wang |Yi He

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Nov 28, 2024 | dx.doi.org | Haoran Wang |Jing Xie |Mengmeng Xiao |Yuehua Ke

Nov 8, 2024 | nature.com | Xiao Qian |Yuduo Guo |Lixin Ma |Haoran Wang |Hongwei Zhang |Shenglun Li | +10 more

Malignant glioma is a highly fatal central nervous system malignancy with high recurrence rates. Oncolytic viruses offer potential treatment but need improvement in efficacy and safety. Here we describe a phase I, dose-escalating, single arm trial (ChiCTR2000032402) to study the safety of Ad-TD-nsIL12, an oncolytic adenovirus expressing non-secreting interleukin-12, in patients with recurrent high-grade glioma that connects with the ventricular system. Eight patients received intratumoral treatment via stereotaxis or an Ommaya reservoir, with doses ranging from 5 × 109 to 5 × 1010vp. The primary end point was to determine the maximal tolerated dose. Secondary endpoints included toxicity and anti-tumour ability. Minimal adverse events were observed at doses of 5 × 109 and 1 × 1010vp. Grade 3 seizure was observed in two patients from Cohort 3 (5 × 1010vp). Therefore, the maximum tolerated dose was determined to be 1 × 1010vp. Four patients developed hydrocephalus during follow-up. Among them, symptoms in two patients were relieved after placement of a ventriculo-peritoneal shunt, and the other two only showed ventriculomegaly on MRI scan without neurological deterioration. Complete response (according to Response Assessment in Neuro-Oncology Criteria) in one patient, a partial response in one patient and post-treatment infiltrations of CD4+ and CD8 + T cells into the tumour were documented during this trial. In conclusion, Ad-TD-nsIL12 has demonstrated safety and preliminary efficacy in patients with recurrent high-grade glioma. Oncolytic viruses have been tested in patients with malignant glioma, however clinical efficacy remains limited. Here the authors report the results of a phase I trial of Ad-TD-nsIL12, an oncolytic adenovirus expressing a mutant (non-secreting) form of IL12, in patients with high-grade glioma.